Oramed Pharmaceuticals Inc.
ORMP | NASDAQ
$4.74
+$0.04 (+0.85%)
Sep 22, 2026, 12:17 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Aug 30, 2021 | FY 2020 Aug 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 1.86 | -5.15 | 16.50 | -12.40 | -25.23 | -6.23 |
PEG Ratio | 0 | 0.01 | -0.14 | -0.51 | -0.64 | 0.20 |
PS Ratio | 59 | n/a | 69.50 | 173.56 | 207.28 | 26.44 |
PB Ratio | 0.59 | 0.68 | 0.57 | 3.09 | 4.84 | 2.18 |
P/FCF Ratio | -10.65 | -11.72 | -8.83 | -16.07 | -25.99 | -5.72 |
P/OCF Ratio | -12.90 | -11.75 | -9.05 | -16.35 | -26.45 | -5.76 |
OCF/S Ratio | -457.25 | n/a | -768.28 | -1.06K | -783.61 | -459.04 |
Debt / Equity Ratio | 0 | 0 | 0.32 | 0.01 | 0 | 0 |
Quick Ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 |
Current Ratio | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 |
Asset Turnover | 0.01 | n/a | 0.01 | 0.02 | 0.02 | 0.06 |
Interest Coverage | n/a | -14.98 | -4.40 | n/a | -4.04K | n/a |
Return on Equity | 32.07% | -13.06% | 3.37% | -24.88% | -19.21% | -35.01% |
Return on Assets | 27.74% | -12.30% | 2.51% | -23.36% | -17.37% | -25.79% |
Return on Invested Capital | -6.05% | -8.53% | -7.21% | -26% | -17.45% | -29.29% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 0.65% | n/a | 100% | 100% | 100% | 96.68% |
Net Profit Margin | 3.2K% | n/a | 412.31% | -1.4K% | -822.72% | -424.76% |
Pretax Profit Margin | 3.77K% | n/a | 379.70% | -1.39K% | -850.50% | -424.76% |
Operating Profit Margin | -754.40% | n/a | -1.18K% | -1.5K% | -896.15% | -433.84% |
FCF Margin | -553.90% | n/a | -787.24% | -1.08K% | -797.48% | -462.07% |
EBITDA Margin | 3.77K% | n/a | 546.34% | -1.37K% | -926.34% | -417.42% |
Add to Watchlist
Select watchlists to add or remove ORMP